Cargando…
Intratumoral Microbiome of Human Primary Liver Cancer
Primary liver tumors (PLCs) and liver metastasis currently represent the leading cause of cancer‐related deaths worldwide due to poor outcomes, high incidence, and postsurgical recurrence. Hence, novel diagnostic markers and therapeutic strategies for PLCs are urgently needed. The human microbiome c...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234634/ https://www.ncbi.nlm.nih.gov/pubmed/35191218 http://dx.doi.org/10.1002/hep4.1908 |
_version_ | 1784736123080146944 |
---|---|
author | Qu, Dingding Wang, Yi Xia, Qingxin Chang, Jing Jiang, Xiangnan Zhang, He |
author_facet | Qu, Dingding Wang, Yi Xia, Qingxin Chang, Jing Jiang, Xiangnan Zhang, He |
author_sort | Qu, Dingding |
collection | PubMed |
description | Primary liver tumors (PLCs) and liver metastasis currently represent the leading cause of cancer‐related deaths worldwide due to poor outcomes, high incidence, and postsurgical recurrence. Hence, novel diagnostic markers and therapeutic strategies for PLCs are urgently needed. The human microbiome can directly or indirectly impact cancer initiation, progression, and response to therapy, including cancer immunotherapy; however, the roles of the microbiota in the tumor microenvironment are not clear and require more investigation. Here, we investigated intratumoral microbial community profiling on formalin‐fixed paraffin‐embedded tissue samples of patients with PLC by 16S ribosomal RNA using the MiSeq platform. We characterized the microbial communities in different histopathological subtypes and in the different prognoses of patients with PLC. The study revealed microbial population differences not only in carcinoma tissue and the matched adjacent nontumor tissue but in different histopathological subtypes, even in patients with PLC with different prognoses. Interestingly, the abundance of certain bacteria that have antitumor effects at family and genus level, such as Pseudomonadaceae, decreased in tumor tissue and was linearly associated with prognosis of patients with PLC. Conclusion: We provide a potential novel diagnostic biomarker and therapeutic strategy for early clinical diagnosis and treatment of PLC. |
format | Online Article Text |
id | pubmed-9234634 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92346342022-06-30 Intratumoral Microbiome of Human Primary Liver Cancer Qu, Dingding Wang, Yi Xia, Qingxin Chang, Jing Jiang, Xiangnan Zhang, He Hepatol Commun Original Articles Primary liver tumors (PLCs) and liver metastasis currently represent the leading cause of cancer‐related deaths worldwide due to poor outcomes, high incidence, and postsurgical recurrence. Hence, novel diagnostic markers and therapeutic strategies for PLCs are urgently needed. The human microbiome can directly or indirectly impact cancer initiation, progression, and response to therapy, including cancer immunotherapy; however, the roles of the microbiota in the tumor microenvironment are not clear and require more investigation. Here, we investigated intratumoral microbial community profiling on formalin‐fixed paraffin‐embedded tissue samples of patients with PLC by 16S ribosomal RNA using the MiSeq platform. We characterized the microbial communities in different histopathological subtypes and in the different prognoses of patients with PLC. The study revealed microbial population differences not only in carcinoma tissue and the matched adjacent nontumor tissue but in different histopathological subtypes, even in patients with PLC with different prognoses. Interestingly, the abundance of certain bacteria that have antitumor effects at family and genus level, such as Pseudomonadaceae, decreased in tumor tissue and was linearly associated with prognosis of patients with PLC. Conclusion: We provide a potential novel diagnostic biomarker and therapeutic strategy for early clinical diagnosis and treatment of PLC. John Wiley and Sons Inc. 2022-02-22 /pmc/articles/PMC9234634/ /pubmed/35191218 http://dx.doi.org/10.1002/hep4.1908 Text en © 2022 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Qu, Dingding Wang, Yi Xia, Qingxin Chang, Jing Jiang, Xiangnan Zhang, He Intratumoral Microbiome of Human Primary Liver Cancer |
title | Intratumoral Microbiome of Human Primary Liver Cancer |
title_full | Intratumoral Microbiome of Human Primary Liver Cancer |
title_fullStr | Intratumoral Microbiome of Human Primary Liver Cancer |
title_full_unstemmed | Intratumoral Microbiome of Human Primary Liver Cancer |
title_short | Intratumoral Microbiome of Human Primary Liver Cancer |
title_sort | intratumoral microbiome of human primary liver cancer |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234634/ https://www.ncbi.nlm.nih.gov/pubmed/35191218 http://dx.doi.org/10.1002/hep4.1908 |
work_keys_str_mv | AT qudingding intratumoralmicrobiomeofhumanprimarylivercancer AT wangyi intratumoralmicrobiomeofhumanprimarylivercancer AT xiaqingxin intratumoralmicrobiomeofhumanprimarylivercancer AT changjing intratumoralmicrobiomeofhumanprimarylivercancer AT jiangxiangnan intratumoralmicrobiomeofhumanprimarylivercancer AT zhanghe intratumoralmicrobiomeofhumanprimarylivercancer |